Non fasting blood glucose (NFBG), fasting blood glucose (FBG) and % HbA1c concentration are shown in Table 2. Significant increases in NFBG, FBG as well as % HbA1c were observed in the untreated diabetic group (DMC) compared to the control rats. The supplementation of RBBO for 12 weeks after STZ induction of diabetic rats reduced the NFBG, FBG and HbA1c level significantly in all the supplemented groups (176.97 to 184.22 mg/dL, 133.31 to 135.70 mg/dL and 4.5 to 4.7%, respectively) when compared to the untreated DMC group (405.51 mg/dL, 212.56 mg/dL and 6.2%), p<0.05. Although supplementation with RBBO reduced blood glucose and % HbA1c, the reduction of blood glucose value was not close to the non-diabetes groups (95.63 to 99.83 mg/dL, 93.10 to 93.30 mg/dL and 4.0%), p < 0.05. Nevertheless, FBG did not differ among RBBO supplemented groups when compared to NC and NR groups. Administration of metformin to diabetic rats significantly reduced the NFBG and FBG as well as % HbA1c (129.00 mg/dL, 123.00 mg/dL, 4.2%) to nearly that of the normal groups as shown in Table 2. Regarding the percentage changes in FBG values among diabetic rats supplemented with RBBO, metformin and DMC, the results demonstrated the significant reduction of FBG by about 25.15 to 27.98% for RBBO supplemented groups and 33.43% for metformin group, when compared to the DMC group as shown in Table 2.
การแปล กรุณารอสักครู่..
